BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 25120245)

  • 21. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
    Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Liu J; Liu B; Yu Y; Chao F; Liu Y; Han X
    Hell J Nucl Med; 2018; 21(1):24-27. PubMed ID: 29550843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K; Hay JH; Wilson DC
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice.
    Kukulska A; Krajewska J; Kołosza Z; Paliczka-Cies Lik E; Puch Z; Gubała E; Król A; Kalemba M; Kropin Ska A; Jarząb B
    Eur J Endocrinol; 2016 Nov; 175(5):379-85. PubMed ID: 27511823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
    Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
    Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
    Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
    Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diagnostic value of positron emission tomography/computed tomography with fluorine-18 fluordeoxyglucose in patients with differentiated thyroid gland carcinoma, high thyroglobulin serum levels and negative iodine whole body scan].
    Yamaga LY; Cunha ML; Wagner J; Thom AF; Daniel MM; Funari MB
    Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):581-6. PubMed ID: 17684619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer.
    Iwano S; Kato K; Ito S; Tsuchiya K; Naganawa S
    Ann Nucl Med; 2012 Apr; 26(3):207-13. PubMed ID: 22160654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic value of 18F-FDG PET/CT in patients with TENIS syndrome: correlation with thyroglobulin levels.
    Özdemir E; Yildirim Poyraz N; Polat SB; Turkolmez S; Ersoy R; Cakir B
    Ann Nucl Med; 2014 Apr; 28(3):241-7. PubMed ID: 24379008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
    Lee J; Nah KY; Kim RM; Oh YJ; An YS; Yoon JK; An GI; Choi TH; Cheon GJ; Soh EY; Chung WY
    J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the role of florine-18 fluorodeoxyglucose/positron emission tomography/computed tomography imaging in well-differentiated thyroid cancers with negative iodine-131 scan high thyroglobulin and normal anti-thyroglobulin levels.
    Döner RK; Sager S; Görtan FA; Topuz ÖV; Akyel R; Vatankulu B; Baran A; Teksoz S; Sönmezoglu K
    J Cancer Res Ther; 2016; 12(2):1010-7. PubMed ID: 27461690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT.
    Seo JH; Lee SW; Ahn BC; Lee J
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):558-63. PubMed ID: 19744107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.